[{"orgOrder":0,"company":"ExpreS2ion Biotechnologies","sponsor":"Gouya Insights | VelaLabs | KKS MedUni Vienna","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ES2B-C001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ExpreS2ion Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExpreS2ion Biotechnologies \/ Gouya Insights | VelaLabs | KKS MedUni Vienna","highestDevelopmentStatusID":"6","companyTruncated":"ExpreS2ion Biotechnologies \/ Gouya Insights | VelaLabs | KKS MedUni Vienna"},{"orgOrder":0,"company":"ExpreS2ion Biotechnologies","sponsor":"Evaxion Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"EVX-V1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ExpreS2ion Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExpreS2ion Biotechnologies \/ ExpreS2ion Biotechnologies","highestDevelopmentStatusID":"4","companyTruncated":"ExpreS2ion Biotechnologies \/ ExpreS2ion Biotechnologies"},{"orgOrder":0,"company":"ExpreS2ion Biotechnologies","sponsor":"The EU Horizon 2020 Consortium","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ExpreS2ion Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExpreS2ion Biotechnologies \/ The EU Horizon 2020 Consortium","highestDevelopmentStatusID":"1","companyTruncated":"ExpreS2ion Biotechnologies \/ The EU Horizon 2020 Consortium"}]

Find Clinical Drug Pipeline Developments & Deals by ExpreS2ion Biotechnologies

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Lead Product(s) : ES2B-C001

                          Therapeutic Area : Oncology

                          Study Phase : Phase I

                          Sponsor : Gouya Insights | VelaLabs | KKS MedUni Vienna

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 24, 2024

                          Lead Product(s) : ES2B-C001

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Gouya Insights | VelaLabs | KKS MedUni Vienna

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Under the terms of the collaboration, ExpreS2ion will have the exclusive right to license the EVX-V1 (CMV vaccine candidate) under a potential development and commercialization agreement.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 12, 2022

                          Lead Product(s) : EVX-V1

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : Evaxion Biotech

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : The aim of the grant is to support the consortium in development of a COVID-19 vaccine candidate, including performing a Phase I/IIa clinical trial.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 03, 2020

                          Lead Product(s) : COVID-19 Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : The EU Horizon 2020 Consortium

                          Deal Size : $0.9 million

                          Deal Type : Funding

                          blank